<?xml version="1.0" encoding="UTF-8"?>
<!DOCTYPE article PUBLIC "-//NLM//DTD Journal Publishing DTD v2.3 20070202//EN" "journalpublishing.dtd">
<article article-type="research-article" dtd-version="2.3" xml:lang="EN" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:xlink="http://www.w3.org/1999/xlink">
<front>
<journal-meta>
<journal-id journal-id-type="publisher-id">Front. Pharmacol.</journal-id>
<journal-title>Frontiers in Pharmacology</journal-title>
<abbrev-journal-title abbrev-type="pubmed">Front. Pharmacol.</abbrev-journal-title>
<issn pub-type="epub">1663-9812</issn>
<publisher>
<publisher-name>Frontiers Media S.A.</publisher-name>
</publisher>
</journal-meta>
<article-meta>
<article-id pub-id-type="publisher-id">770558</article-id>
<article-id pub-id-type="doi">10.3389/fphar.2021.770558</article-id>
<article-categories>
<subj-group subj-group-type="heading">
<subject>Pharmacology</subject>
<subj-group>
<subject>Original Research</subject>
</subj-group>
</subj-group>
</article-categories>
<title-group>
<article-title>Synergetic Effect of 4-Phenylbutyric Acid in Combination with Cyclosporine A on Cardiovascular Function in Sepsis Rats via Inhibition of Endoplasmic Reticulum Stress and Mitochondrial Permeability Transition Pore Opening</article-title>
<alt-title alt-title-type="left-running-head">Kuang et&#x20;al.</alt-title>
<alt-title alt-title-type="right-running-head">PBA and CsA Benefited Sepsis</alt-title>
</title-group>
<contrib-group>
<contrib contrib-type="author">
<name>
<surname>Kuang</surname>
<given-names>Lei</given-names>
</name>
<uri xlink:href="https://loop.frontiersin.org/people/722226/overview"/>
</contrib>
<contrib contrib-type="author">
<name>
<surname>Zhu</surname>
<given-names>Yu</given-names>
</name>
</contrib>
<contrib contrib-type="author">
<name>
<surname>Wu</surname>
<given-names>Yue</given-names>
</name>
</contrib>
<contrib contrib-type="author">
<name>
<surname>Peng</surname>
<given-names>Xiaoyong</given-names>
</name>
<uri xlink:href="https://loop.frontiersin.org/people/1454540/overview"/>
</contrib>
<contrib contrib-type="author">
<name>
<surname>Tian</surname>
<given-names>Kunlun</given-names>
</name>
</contrib>
<contrib contrib-type="author" corresp="yes">
<name>
<surname>Liu</surname>
<given-names>Liangming</given-names>
</name>
<xref ref-type="fn" rid="fn1">
<sup>&#x2020;</sup>
</xref>
<xref ref-type="corresp" rid="c001">&#x2a;</xref>
<uri xlink:href="https://loop.frontiersin.org/people/24483/overview"/>
</contrib>
<contrib contrib-type="author">
<name>
<surname>Li</surname>
<given-names>Tao</given-names>
</name>
<xref ref-type="fn" rid="fn1">
<sup>&#x2020;</sup>
</xref>
<xref ref-type="corresp" rid="c001">&#x2a;</xref>
<uri xlink:href="https://loop.frontiersin.org/people/639195/overview"/>
</contrib>
</contrib-group>
<aff>
<institution>Department of Shock and Transfusion, State Key Laboratory of Trauma, Burns and Combined Injury, Daping Hospital, Third Military Medical University (Army Medical University)</institution>, <addr-line>Chongqing</addr-line>, <country>China</country>
</aff>
<author-notes>
<fn fn-type="edited-by">
<p>
<bold>Edited by:</bold> <ext-link ext-link-type="uri" xlink:href="https://loop.frontiersin.org/people/475616/overview">Mahmoud El-Mas</ext-link>, Alexandria University, Egypt</p>
</fn>
<fn fn-type="edited-by">
<p>
<bold>Reviewed by:</bold> <ext-link ext-link-type="uri" xlink:href="https://loop.frontiersin.org/people/978137/overview">Mohamed A. Saleh</ext-link>, University of Sharjah, United Arab Emirates</p>
<p>
<ext-link ext-link-type="uri" xlink:href="https://loop.frontiersin.org/people/993547/overview">Timoteo Marchini</ext-link>, University Heart Center Freiburg, Germany</p>
</fn>
<corresp id="c001">&#x2a;Correspondence: Liangming Liu, <email>liangmingliu@yahoo.com</email>; Tao Li, <email>lt200132@163.com</email>
</corresp>
<fn fn-type="equal" id="fn1">
<label>
<sup>&#x2020;</sup>
</label>
<p>These authors have contributed equally to this&#x20;work</p>
</fn>
<fn fn-type="other">
<p>This article was submitted to Cardiovascular and Smooth Muscle Pharmacology, a section of the journal Frontiers in Pharmacology</p>
</fn>
</author-notes>
<pub-date pub-type="epub">
<day>30</day>
<month>11</month>
<year>2021</year>
</pub-date>
<pub-date pub-type="collection">
<year>2021</year>
</pub-date>
<volume>12</volume>
<elocation-id>770558</elocation-id>
<history>
<date date-type="received">
<day>04</day>
<month>09</month>
<year>2021</year>
</date>
<date date-type="accepted">
<day>01</day>
<month>11</month>
<year>2021</year>
</date>
</history>
<permissions>
<copyright-statement>Copyright &#xa9; 2021 Kuang, Zhu, Wu, Peng, Tian, Liu and Li.</copyright-statement>
<copyright-year>2021</copyright-year>
<copyright-holder>Kuang, Zhu, Wu, Peng, Tian, Liu and Li</copyright-holder>
<license xlink:href="http://creativecommons.org/licenses/by/4.0/">
<p>This is an open-access article distributed under the terms of the Creative Commons Attribution License (CC BY). The use, distribution or reproduction in other forums is permitted, provided the original author(s) and the copyright owner(s) are credited and that the original publication in this journal is cited, in accordance with accepted academic practice. No use, distribution or reproduction is permitted which does not comply with these&#x20;terms.</p>
</license>
</permissions>
<abstract>
<p>
<bold>Background:</bold> Sepsis/septic shock is a common complication in the intensive care unit, and the opening of the mitochondrial permeability transition pore (mPTP), as well as the endoplasmic reticulum stress (ERS), play important roles in this situation. Whether the combination of anti-ERS and anti-mPTP by 4-phenylbutyric acid (PBA) and Cyclosporine A (CsA) could benefit sepsis is unclear.</p>
<p>
<bold>Methods:</bold> The cecal ligation and puncture-induced septic shock models were replicated in rats, and lipopolysaccharide (LPS)-challenged primary vascular smooth muscle cells and H9C2 cardiomyocytes <italic>in&#x20;vitro</italic> models were also used. The therapeutic effects of CsA, PBA, and combined administration on oxygen delivery, cardiac and vascular function, vital organ injury, and the underlying mechanisms were observed.</p>
<p>
<bold>Results:</bold> Septic shock significantly induced cardiovascular dysfunction, hypoperfusion, and organ injury and resulted in high mortality in rats. Conventional treatment including fluid resuscitation, vasoactive agents, and antibiotics slightly restored tissue perfusion and organ function in septic rats. Supplementation of CsA or PBA improved the tissue perfusion, organ function, and survival of septic shock rats. The combined application of PBA and CsA could significantly enhance the beneficial effects, compared with using PBA or CsA alone. Further study showed that PBA enhanced CsA-induced cardiovascular protection, which contributed to better therapeutic effects.</p>
<p>
<bold>Conclusion:</bold> Anti-ERS and anti-mPTP-opening by the combination of PBA and CsA was beneficial to septic shock. PBA enforced the CsA-associated cardiovascular protection and contributed to the synergetic effect.</p>
</abstract>
<kwd-group>
<kwd>sepsis</kwd>
<kwd>cardiovascular function</kwd>
<kwd>synergetic effects</kwd>
<kwd>endoplasmic reticulum stress</kwd>
<kwd>mitochondrial permeability transition pore opening</kwd>
</kwd-group>
</article-meta>
</front>
<body>
<sec id="s1">
<title>Introduction</title>
<p>Sepsis/septic shock is a common and severe complication in the intensive care unit. Despite substantial advances in the development of medicine and therapeutics, the mortality of severe sepsis remains high (<xref ref-type="bibr" rid="B3">Cecconi et&#x20;al., 2018</xref>). Studies have demonstrated that tissue hypoperfusion and/or organ dysfunction play critical roles in severe sepsis- or septic shock-associated morbidity and mortality. Impairment in tissue hypoperfusion or oxygen availability induced by hemodynamic disturbances in the macro- and micro-circulatory are considered to be the main reasons for organ dysfunction following severe sepsis and septic shock (<xref ref-type="bibr" rid="B33">Zanotti-Cavazzoni and Hollenberg, 2009</xref>). The measures of protecting cardiovascular dysfunction may be the ideal treatment for sepsis.</p>
<p>Mitochondria are the center of energy metabolism and play important roles in the regulation of cell functions. Studies suggested that the degree of mitochondrial dysfunction in vital organs is associated with organ injury and mortality following sepsis (<xref ref-type="bibr" rid="B24">Pool et&#x20;al., 2018</xref>; <xref ref-type="bibr" rid="B27">Supinski et&#x20;al., 2020</xref>). Mitochondrial permeability transition pore (mPTP) is a nonspecific pore that plays important roles in the regulation of mitochondrial structure and function. Upon mPTP opening, free passage of protons across the inner membrane leads to dissipation of the membrane potential and pH gradient which comprise oxidative phosphorylation. mPTP opening results in disturbances in energy metabolism and cell damage (<xref ref-type="bibr" rid="B30">van Gurp et&#x20;al., 2003</xref>; <xref ref-type="bibr" rid="B15">Leung and Halestrap, 2008</xref>). Several studies have demonstrated that mPTP opening participates in cardiovascular damage after ischemia-reperfusion, and anti-mPTP opening with Cyclosporine A (CsA) has a beneficial effect on ischemia-reperfusion injury in the heart, but its effect is limited (<xref ref-type="bibr" rid="B23">Morciano et&#x20;al., 2017</xref>). We want to know whether other measures could enhance the beneficial effect of&#x20;CsA.</p>
<p>Some studies have suggested that endoplasmic reticulum stress (ERS) contributed to mPTP opening. ERS stimulator, streptovirudin, leads to dephosphorylation of AKT and its target glycogen synthase kinase-3&#x3b2; which results in cardiac dysfunction, and these effects are antagonized by CsA (<xref ref-type="bibr" rid="B34">Zhang et&#x20;al., 2013</xref>). Other studies demonstrated that ERS has important roles in the development of heart failure, hypertension, and atherosclerosis (<xref ref-type="bibr" rid="B11">Hong et&#x20;al., 2017</xref>) and sepsis-induced cardiovascular dysfunction (<xref ref-type="bibr" rid="B13">Khan et&#x20;al., 2015</xref>). Hence, we hypothesize that anti-ERS combined with CsA is beneficial to septic shock via enhancing cardiovascular protection.</p>
<p>To test this hypothesis, cecal ligation and puncture (CLP)-induced septic shock rats, as well as lipopolysaccharide (LPS)-treated vascular smooth muscle cells (VSMCs) and H9C2 cardiomyocyte cell line, were employed. The synergetic effects of CsA in combination with PBA on septic shock and the underlying mechanism were observed.</p>
</sec>
<sec sec-type="materials|methods" id="s2">
<title>Materials and Methods</title>
<sec id="s2-1">
<title>Ethical Approval of the Study</title>
<p>The study was approved by the Laboratory Animal Welfare and Ethics Committee of Third Military Medical University (Army Medical University) according to the guidelines of the ethical use of animals. The protocol conformed to the guidelines of the ethical use of animals. The investigation conformed to the Guide for the Care and Use of Laboratory Animals published by the US National Institutes of Health (NIH Publications, eighth edition, 2011), and all rats were guaranteed to suffer the least amount.</p>
</sec>
<sec id="s2-2">
<title>Animals and Materials</title>
<p>A total number of 296 male and female Sprague&#x2013;Dawley rats (220&#x2013;240&#xa0;g) were obtained from the Animal Center of Army Medical Center. They were maintained in a room at constant humidity (60&#x20;&#xb1; 5%), temperature (24&#x20;&#xb1; 1&#xb0;C), and light cycle (6&#xa0;am&#x2013;6&#xa0;pm) and fed standard pellet diets ad libitum. 4-Phenylbutyric acid (PBA, &#x23;P21005), Cyclosporin A (CsA, &#x23;SML1018), betulinc acid (Betu, &#x23;B8936), and Calcein-AM (&#x23;17783) were purchased from Sigma-Aldrich; MitoTracker DeepRed FM (&#x23;M22426) was purchased from Thermo Fisher Scientific. Anti-ANT1 antibody (&#x23;ab110322), anti-GRP78 antibody (&#x23;ab21685), and GRP94 antibody (&#x23;ab238126) were purchased from Abcam. Anti-VDAC1 antibody (&#x23;A19707) and anti-CypD (Cyclophilin 40) antibody (&#x23;A5097) were purchased from Abclonal. Anti-CHOP antibody (&#x23;2895) was purchased from Cell Signaling Technology. Anti-&#x3b2;-actin antibody (&#x23;MA1-744) and anti-GAPDH (&#x23;A21994) antibodies were purchased from Thermo Fisher Scientific.</p>
</sec>
<sec id="s2-3">
<title>Septic Shock Rat Model Establishment</title>
<p>Rats were anaesthetized with sodium pentobarbital (30&#xa0;mg/kg, i.p.) before operation. After sterilization, the cecum was exposed and ligated by 7.5&#xa0;mm to its end. The ligated cecum was punctured (&#x2248;1.5&#xa0;mm) with a triangular needle (sham-operated rats only received cecum ligation and no puncture). Feces were allowed to flow into the abdominal cavity. After the closure of the abdomen, rats were returned to their cages and allowed food and water ad libitum. Twelve hours after surgery, rats were re-anaesthetized and the femoral artery was catheterized (PE9050, inner diameter &#x3d; 0.5&#xa0;mm, SDR scientific), and mean arterial pressure (MAP) was measured. If MAP was &#x3c;70&#xa0;mmHg or if it decreased by &#x3e;30% (compared with the sham-operated level), septic shock model was considered replicated. The success rate of septic shock was&#x20;89.2%.</p>
</sec>
<sec id="s2-4">
<title>Fluid Therapy</title>
<p>Septic shock rats were randomly assigned into 4 groups receiving conventional therapy (CT), CsA (anti-mPTP opening), PBA (anti-ERS), and CsA &#x2b; PBA. Conventional therapy consists of infusion of lactated Ringer&#x2019;s solution (LR) through the right femoral vein, dopamine supplementation whenever necessary to maintain MAP &#x3e;70&#xa0;mmHg, and antibiotic (cefuroxime sodium, 50&#xa0;mg/kg i.m.). Fluid was infused within 3&#xa0;h and the total fluid volume was 30&#xa0;ml/kg, and the maximum rate of dopamine infusion was &#x2264;10&#xa0;&#x3bc;g/kg/min. CsA (5&#xa0;mg/kg) and PBA (5&#xa0;mg/kg) were dissolved in LR and administered during fluid therapy. The following parameters were collected 6&#xa0;h after infusion.</p>
</sec>
<sec id="s2-5">
<title>Blood Flow and Organ Function</title>
<p>The tissue blood flow of the intestine and kidney were measured by a laser Periflux System 5,000 Doppler system (Perimed, Sweden) as described in our lab previously (<xref ref-type="bibr" rid="B20">Li et&#x20;al., 2013</xref>). The abdomen cavity was opened and the probes were placed on the surface of vital organs. Biochemical variables including blood levels of <sc>d</sc>-lactate were measured with commercially available kits (Nanjing Jiancheng Bioengineering Institute, &#x23;H263), blood endotoxin, blood urea nitrogen (BUN), and serum creatinine (Scr) were measured by a DX800 Biochemical Analyzer (Beckman Coulter, United&#x20;States). The volume of blood samples for measurement of biochemical analysis was 1.0&#x2013;1.5&#xa0;ml.</p>
</sec>
<sec id="s2-6">
<title>Hemodynamic Parameters, Oxygen Delivery, and Utilization</title>
<p>The cardiac output (CO) was measured with thermodilution techniques as described previously (<xref ref-type="bibr" rid="B21">Liu et&#x20;al., 2016</xref>). A thermodilution probe was inserted into the aorta ascendens of the rat through the right carotid artery, and 0.3&#xa0;ml ice-bathed saline was injected through the right external jugular vein catheter. The CO was determined using a CO analyzer (PowerLab, AD Instruments, Australia). Arterial and venous blood gases were measured using a pHOx<sup>&#xae;</sup> plus L Blood Gas Analyzer (Nova Biomedical, United&#x20;States) with blood from the femoral artery and femoral vein. The volume of blood samples for measurement of blood gases was 0.3&#xa0;ml and to avoid additional blood loss in rats, equal volumes of blood from donor rats were infused back after each sample was taken. Oxygen delivery (DO<sub>2</sub>) and oxygen consumption (VO<sub>2</sub>) were calculated using the following equations:<disp-formula id="equ1">
<mml:math id="m1">
<mml:mrow>
<mml:msub>
<mml:mrow>
<mml:mtext>DO</mml:mtext>
</mml:mrow>
<mml:mn>2</mml:mn>
</mml:msub>
<mml:mo>&#x3d;</mml:mo>
<mml:mtext>CI&#xd7;</mml:mtext>
<mml:mn>13</mml:mn>
<mml:mtext>.</mml:mtext>
<mml:mn>4</mml:mn>
<mml:mtext>&#xd7;</mml:mtext>
<mml:mrow>
<mml:mo>[</mml:mo>
<mml:mrow>
<mml:mtext>Hb</mml:mtext>
</mml:mrow>
<mml:mo>]</mml:mo>
</mml:mrow>
<mml:msub>
<mml:mrow>
<mml:mtext>&#xd7;SaO</mml:mtext>
</mml:mrow>
<mml:mn>2</mml:mn>
</mml:msub>
</mml:mrow>
</mml:math>
</disp-formula>
<disp-formula id="equ2">
<mml:math id="m2">
<mml:mrow>
<mml:msub>
<mml:mrow>
<mml:mtext>VO</mml:mtext>
</mml:mrow>
<mml:mn>2</mml:mn>
</mml:msub>
<mml:mo>&#x3d;</mml:mo>
<mml:mtext>CI&#xd7;</mml:mtext>
<mml:mn>13</mml:mn>
<mml:mtext>.</mml:mtext>
<mml:mn>4</mml:mn>
<mml:mtext>&#xd7;</mml:mtext>
<mml:mrow>
<mml:mo>[</mml:mo>
<mml:mrow>
<mml:mtext>Hb</mml:mtext>
</mml:mrow>
<mml:mo>]</mml:mo>
</mml:mrow>
<mml:mtext>&#xd7;</mml:mtext>
<mml:mrow>
<mml:mo>(</mml:mo>
<mml:mrow>
<mml:msub>
<mml:mrow>
<mml:mtext>SaO</mml:mtext>
</mml:mrow>
<mml:mn>2</mml:mn>
</mml:msub>
<mml:msub>
<mml:mrow>
<mml:mtext>&#xa0;</mml:mtext>
<mml:mo>-</mml:mo>
<mml:mtext>SvO</mml:mtext>
</mml:mrow>
<mml:mn>2</mml:mn>
</mml:msub>
</mml:mrow>
<mml:mo>)</mml:mo>
</mml:mrow>
</mml:mrow>
</mml:math>
</disp-formula>
</p>
<p>CI in the equations is the cardiac index, [Hb] is the hemoglobin concentration, SaO<sub>2</sub> is the oxygen saturation of the artery, and SvO<sub>2</sub> is the oxygen saturation of the vein (<xref ref-type="bibr" rid="B18">Li et&#x20;al., 2011a</xref>).</p>
</sec>
<sec id="s2-7">
<title>Contractile Tension of Cardiac Muscle</title>
<p>The contractile tension of cardiac muscle was measured with the Powerlab system (AD Instruments, Australia) (<xref ref-type="bibr" rid="B19">Li et&#x20;al., 2010a</xref>). Briefly, a small bundle of cardiac papillary muscle (CPM, diameter &#x3c;1mm; length &#x2248;5&#xa0;mm) was dissected from the right ventricle. Then, it was mounted and suspended between the fixation hooks, and then immersed in an isolated organ chamber (Scientific Instruments, Spain) containing 37&#xb0;C Krebs-Henseleit (K-H) solution (mmol/L): NaCl 120, KCl 4.7, NaH<sub>2</sub>PO<sub>4</sub> 1.2, MgSO<sub>4</sub> 1.2, CaCl<sub>2</sub> 2.5, NaHCO<sub>3</sub> 20, glucose 10 (pH 7.4) bubbled continuously with 95% O<sub>2</sub>/5% CO<sub>2</sub>. The CPM was given 1.0&#xa0;g of preload for 60&#xa0;min, and then received an electric stimulus (0.1&#xa0;mV; frequency, 0.2&#xa0;Hz; duration, 10&#xa0;ms). The CPM was perfused with isoprenaline (ISO) of a series of concentrations (1&#xd7;10<sup>&#x2212;10</sup>&#x2013;1&#xd7;10<sup>&#x2212;4</sup>&#xa0;mol/L) and the contractile tension of CPM at each concentration of ISO was determined.</p>
</sec>
<sec id="s2-8">
<title>Vascular Reactivity of Superior Mesenteric Artery</title>
<p>Vascular contractile and dilative function was expressed as the responsiveness of arteries to the norepinephrine (NE) or acetylcholine (Ach), as described previously (<xref ref-type="bibr" rid="B35">Zhu et&#x20;al., 2013</xref>). The response of arteries to NE was measured by the PowerLab system via a force transducer (AD Instruments, Australia). SMA rings (diameter, 2&#x2013;3&#xa0;mm) were mounted on wire and suspended between a force transducer and a post attached to a micrometer, then immersed into an isolated organ chamber containing K-H solution. After equilibration for 2&#xa0;h, the contractile responses of arterial rings to NE (1&#xd7;10<sup>&#x2212;10</sup>&#x2013;1&#xd7;10<sup>&#x2212;4</sup>&#xa0;mol/L) were measured. The dilative responses of arterial rings to Ach (1&#xd7;10<sup>&#x2212;10</sup>&#x2013;1&#xd7;10<sup>&#x2212;4</sup>&#xa0;mol/L) were measured subsequently.</p>
</sec>
<sec id="s2-9">
<title>Cell Culture and Transfection</title>
<p>VSMCs were obtained from the mesenteric arteries of SD rats by enzymatic digestion as described previously in our research team (<xref ref-type="bibr" rid="B17">Li et&#x20;al., 2010b</xref>; <xref ref-type="bibr" rid="B16">Li et&#x20;al., 2011b</xref>). Briefly, isolate the whole mesenteric bed and place it in cold complete DMEM high glucose medium (Gibco, 12430047), clean the mesenteric bed by carefully removing the fat, incubate the mesenteric bed in a centrifuge tube containing the pre-digestion mix (DMEM, with collagenase type I from Sangon, &#x23;A004194) for 30&#xa0;min, homogenize the vascular bed by syringing with 20G needle four times, filter cells and tissue debris through a 100&#xa0;&#x3bc;m nylon filter, and collect the cell solution. Centrifuge the cell solution and resuspend the cell pellet in 5&#xa0;ml of DMEM with 10% FBS (Gibco, 10099141) and culture the cells in a 37&#xb0;C/5% CO<sub>2</sub> incubator. Keep changing the medium every 2&#xa0;days until cells reach confluence and are ready for either further culture. Rat cardiomyocyte cell line (H9C2) was obtained from ATCC and grown in DMEM high glucose and supplemented with 10% FBS. Before each experiment, cells were serum-starved for 12&#xa0;h.</p>
<p>CHOP siRNA (GGA AAC GAA GAG GAA GAA UTT; AUU CUU CCU CUU CGU UUC CTT) and Lipofectamine 3,000 (Invitrogen, L3000015) were used for decreasing CHOP expression. Cells were seeded at 2&#x20;&#xd7; 10<sup>5</sup> cells/well on 6-well plate or 35&#xa0;mm confocal dish &#x223c;24&#xa0;h before transfection. Transfections were performed in OPTI-MEM media (Gibco, 31985062) with 3&#xa0;uL and 5&#xa0;&#x3bc;L Lipofectamine 3,000 per well/dish for primary VSMCs and&#x20;H9C2 cells, respectively, and 3&#xa0;&#x3bc;g of siRNA were used per well/dish. The expression of the target protein was detected by immunoblotting or confocal microscope 48&#x2013;72&#xa0;h post-transfection.</p>
</sec>
<sec id="s2-10">
<title>Mitochondrial Permeability Transition Pore Opening Observation</title>
<p>The extent of opening of the mPTP was determined by the calcein&#x2013;Co<sup>2&#x2b;</sup> method using laser scanning confocal microscopy, as described previously (<xref ref-type="bibr" rid="B5">Duan et&#x20;al., 2020</xref>). Briefly, VSMCs or H9C2 cardiomyocytes were seeded in 35&#x20;mm petri dishes and incubated with 2&#xa0;&#xb5;M calcein-AM and 100&#xa0;nM MitoTracker DeepRed for 30&#xa0;min and then exposed to 2&#xa0;mM CoCl<sub>2</sub> for 15&#xa0;min at room temperature. Cells were then observed with a Leica TCS SP5 confocal system (Leica Microsystems, Germany), excited at 488&#xa0;nm (calcein-AM) and 633&#xa0;nm (MitoTracker Deep Red). When the mPTP opened, calcein-AM flowed out from mitochondria and fluorescence decreased. The mPTP opening was indicated by the decreased fluorescence intensity of calcein.</p>
</sec>
<sec id="s2-11">
<title>Immunoblotting</title>
<p>Myocardium, superior mesenteric artery, VSMCs, and H9C2 cardiomyocytes were harvested and lysed, and protein extracts were separated by SDS-PAGE and transferred to nitrocellulose filter membrane, then immunoblotted with corresponding antibodies at a dilution of 1:1,000 (VDAC, CypD, ANT, CHOP, GRP78, GRP94, &#x3b2;-actin) and IRDye secondary antibodies (Li-Cor, United&#x20;States) and analyzed with Odyssey CLx Imaging System (Li-cor, United&#x20;States).</p>
</sec>
<sec id="s2-12">
<title>Statistical Analyses</title>
<p>Parametric data were presented as the mean&#x20;&#xb1; standard deviation of n observations. The statistical differences among groups were analyzed by ANOVA analysis, followed by the post-hoc Tukey test for multiple comparisons between groups. Survival was analyzed by Kaplan-Meier survival analysis and the log-rank test. <italic>p</italic>&#x20;&#x3c; 0.05 was considered significant.</p>
</sec>
</sec>
<sec sec-type="results" id="s3">
<title>Results</title>
<sec>
<title>Synergetic Effects of PBA and CsA on Improving Animal Survival, Oxygen Delivery, and Utilization, Blood Gas Following Sepsis in&#x20;Rats</title>
<p>The results showed that after septic shock, the MAP of rats was significantly decreased. Conventional therapy (CT) could increase and maintain MAP to about 80&#xa0;mmHg in rats during fluid infusion, and then MAP tended to decrease after infusion. Supplementation of CsA or PBA alone was able to maintain MAP at about 88&#x20;&#xb1; 4.2&#xa0;mmHg and 92&#x20;&#xb1; 4.8&#xa0;mmHg, and combined administration of PBA and CsA significantly improved the MAP (102&#x20;&#xb1; 4.4&#xa0;mmHg), compared with using PBA or CsA alone (<xref ref-type="fig" rid="F1">Figure&#x20;1A</xref>).</p>
<fig id="F1" position="float">
<label>FIGURE 1</label>
<caption>
<p>Synergetic effect of PBA and CsA on improving survival and oxygen delivery in CLP-induced septic shock rats. <bold>(A)</bold>, mean arterial pressure (MAP) (<italic>n</italic>&#x20;&#x3d; 8/group); <bold>(B)</bold>, oxygen delivery (DO<sub>2</sub>) (<italic>n</italic>&#x20;&#x3d; 8/group); <bold>(C)</bold>, oxygen utilization (VO<sub>2</sub>) (<italic>n</italic>&#x20;&#x3d; 8/group); <bold>(D)</bold>, survival rate and survival time (<italic>n</italic>&#x20;&#x3d; 16/group). CsA, cyclosporine A; PBA, 4-phenylbutyrate; CT, conventional treatment; NT, no treatment. &#x2a;<italic>p</italic>&#x20;&#x3c; 0.05, &#x2a;&#x2a;<italic>p</italic>&#x20;&#x3c; 0.01, &#x2a;&#x2a;&#x2a;<italic>p</italic>&#x20;&#x3c; 0.001.</p>
</caption>
<graphic xlink:href="fphar-12-770558-g001.tif"/>
</fig>
<p>CT moderately restored PaO<sub>2</sub>, SaO<sub>2</sub>, SvO<sub>2</sub>; however, the oxygen delivery (DO<sub>2</sub>) and utilization (VO<sub>2</sub>) were not increased. Supplementation of CsA or PBA alone significantly increased PaO<sub>2</sub>, SaO<sub>2</sub>, SvO<sub>2</sub>, DO<sub>2</sub>, and VO<sub>2</sub>, PBA, and CsA demonstrated similar effects. Combined administration of PBA and CsA significantly improved DO<sub>2</sub>, VO<sub>2</sub>, compared with PBA or CsA alone (<xref ref-type="fig" rid="F1">Figures 1B,C</xref> and <xref ref-type="table" rid="T1">Table&#x20;1</xref>).</p>
<table-wrap id="T1" position="float">
<label>TABLE 1</label>
<caption>
<p>Synergetic effects of PBA &#x2b; CsA on blood gas following sepsis.</p>
</caption>
<table>
<thead valign="top">
<tr>
<th align="left">Group</th>
<th align="left">Baseline</th>
<th align="left">Sepsis</th>
<th align="left">6&#xa0;h after Treatment</th>
</tr>
</thead>
<tbody valign="top">
<tr>
<td align="left">PaO<sub>2</sub> (mmHg)</td>
<td align="left"/>
<td align="left"/>
<td align="left"/>
</tr>
<tr>
<td align="left">&#x2003;NT</td>
<td rowspan="5" align="char" char="plusmn">99.2&#x20;&#xb1; 8.6</td>
<td rowspan="5" align="char" char="plusmn">93.6&#x20;&#xb1; 8.8</td>
<td align="char" char="plusmn">88.9&#x20;&#xb1; 10.5</td>
</tr>
<tr>
<td align="left">&#x2003;CT</td>
<td align="char" char="plusmn">94.7&#x20;&#xb1; 10.2</td>
</tr>
<tr>
<td align="left">&#x2003;CsA</td>
<td align="char" char="plusmn">96.7&#x20;&#xb1; 10.8</td>
</tr>
<tr>
<td align="left">&#x2003;PBA</td>
<td align="char" char="plusmn">97.3&#x20;&#xb1; 7.9</td>
</tr>
<tr>
<td align="left">&#x2003;CsA &#x2b; PBA</td>
<td align="char" char="plusmn">99.4&#x20;&#xb1; 5.3</td>
</tr>
<tr>
<td align="left">SaO<sub>2</sub> (%)</td>
<td align="left"/>
<td align="left"/>
<td align="left"/>
</tr>
<tr>
<td align="left">&#x2003;NT</td>
<td rowspan="5" align="char" char="plusmn">98.8&#x20;&#xb1; 0.9</td>
<td rowspan="5" align="char" char="plusmn">91.3&#x20;&#xb1; 1.8</td>
<td align="char" char="plusmn">84.2&#x20;&#xb1; 1.4</td>
</tr>
<tr>
<td align="left">&#x2003;CT</td>
<td align="char" char="plusmn">92.8&#x20;&#xb1; 2.5</td>
</tr>
<tr>
<td align="left">&#x2003;CsA</td>
<td align="char" char="plusmn">96.4&#x20;&#xb1; 2.2&#x2a;</td>
</tr>
<tr>
<td align="left">&#x2003;PBA</td>
<td align="char" char="plusmn">95.4&#x20;&#xb1; 1.5<sup>@</sup>
</td>
</tr>
<tr>
<td align="left">&#x2003;CsA &#x2b; PBA</td>
<td align="char" char="plusmn">99.3&#x20;&#xb1; 1&#x2a;&#x2a;</td>
</tr>
<tr>
<td align="left">SvO<sub>2</sub> (%)</td>
<td align="left"/>
<td align="left"/>
<td align="left"/>
</tr>
<tr>
<td align="left">&#x2003;NT</td>
<td rowspan="5" align="char" char="plusmn">58.7&#x20;&#xb1; 3.9</td>
<td rowspan="5" align="char" char="plusmn">44.1&#x20;&#xb1; 4</td>
<td align="char" char="plusmn">42.4&#x20;&#xb1; 3.7</td>
</tr>
<tr>
<td align="left">&#x2003;CT</td>
<td align="char" char="plusmn">45.4&#x20;&#xb1; 6.1</td>
</tr>
<tr>
<td align="left">&#x2003;CsA</td>
<td align="char" char="plusmn">47.5&#x20;&#xb1; 5.1</td>
</tr>
<tr>
<td align="left">&#x2003;PBA</td>
<td align="char" char="plusmn">47.8&#x20;&#xb1; 5.4</td>
</tr>
<tr>
<td align="left">&#x2003;CsA &#x2b; PBA</td>
<td align="char" char="plusmn">51.6&#x20;&#xb1; 4.4&#x2a;</td>
</tr>
</tbody>
</table>
<table-wrap-foot>
<fn>
<p>CLP, cecal ligation and puncture; NT, no treatment; CT, conventional therapy; CsA, cyclosporine A; PBA, 4-phenylbutyrate acid. PaO<sub>2</sub>, partial pressure of oxygen in artery; SaO<sub>2</sub> and SvO2, arterial and venous oxygen saturation. &#x2a;<italic>p</italic>&#x20;&#x3c; 0.05, &#x2a;&#x2a;<italic>p</italic>&#x20;&#x3c; 0.01 vs CT; <sup>@</sup> <italic>p</italic>&#x20;&#x3c; 0.05, vs PBA &#x2b; CsA.</p>
</fn>
</table-wrap-foot>
</table-wrap>
<p>The animal survival time and the survival rate were significantly decreased following sepsis. Conventional therapy slightly improved animal survival (although not significant). Besides, in the PBA &#x2b; CsA group, the 72&#xa0;h survival rate of rats was 9/16, while it was only 3/16 in the CsA group and 4/16 in the PBA group. The average survival time was also significantly increased with the combined administration of CsA and PBA (<xref ref-type="fig" rid="F1">Figures&#x20;1D,E</xref>).</p>
</sec>
<sec>
<title>Synergetic Effects of PBA and CsA on Increasing Tissue Perfusion and Organ Function Following Sepsis in&#x20;Rats</title>
<p>To further clarify the role of CsA, PBA, and the combined administration in septic shock, we observed the changes in tissue blood flow and organ function before and after infusion in septic shock rats. The results showed that the tissue blood flow of the kidney and small intestine were significantly decreased after septic shock in rats compared with sham-operated rats (<xref ref-type="fig" rid="F2">Figures 2A,D</xref>). Conventional therapy failed to improve the intestinal or renal perfusion following septic shock. CsA or PBA slightly improved the blood flow of the kidney and tended to increase the blood flow of the small intestine. CsA &#x2b; PBA significantly increased blood perfusion of intestine and kidney, compared with the CsA group, and the average blood flow of kidney and intestine were increased by 32.1 and 52.8%, respectively. The organ functions were significantly impaired after septic shock, and it was shown that the level of blood urine nitrogen, serum creatinine, <sc>d</sc>-lactate, and endotoxin were significantly increased (<xref ref-type="fig" rid="F2">Figures 2B,C,E,F</xref>). Conventional therapy demonstrated limited effects in restoring organ injury. CsA or PBA alleviated the damage of organs. The combination of PBA with CsA significantly reduced the damage of organ function as compared with CsA or PBA&#x20;alone.</p>
<fig id="F2" position="float">
<label>FIGURE 2</label>
<caption>
<p>Synergetic effect of PBA and CsA on improving tissue perfusion and organ function in CLP-induced septic shock rats. (<italic>n</italic>&#x20;&#x3d; 8/group) <bold>(A)</bold>, the blood flow of intestine; <bold>(B-C)</bold>, intestinal barrier injury indices (<sc>d</sc>-lactate and endotoxin); <bold>(D)</bold>, the blood flow of kidney; <bold>(E-F)</bold>, renal function (blood urea nitrogen and serum creatinine). CsA, cyclosporine A; PBA, 4-phenylbutyrate acid; CT, conventional treatment. &#x2a;<italic>p</italic>&#x20;&#x3c; 0.05, &#x2a;&#x2a;<italic>p</italic>&#x20;&#x3c; 0.01, &#x2a;&#x2a;&#x2a;<italic>p</italic>&#x20;&#x3c; 0.001.</p>
</caption>
<graphic xlink:href="fphar-12-770558-g002.tif"/>
</fig>
</sec>
<sec id="s3-1">
<title>Phenylbutyric Acid and Cyclosporine A Synergetically Induced the Improvement of Cardiovascular Function Following Septic Shock</title>
<p>Cardiovascular dysfunction directly impairs tissue perfusion. Previous studies demonstrated that cardiovascular function was decreased after sepsis or septic shock, the damage degree of cardiovascular function was positively correlated with mortality of septic shock. In this section, the effects of the combination of PBA and CsA on cardiovascular function including the cardiac and vascular contractile reactivity, cardiac output, and cardiac index were investigated.</p>
<p>The results showed that the contractile forces of CPM and SMA to catecholamines (ISO and NE), and the cardiac output, cardiac index, and stroke index were significantly decreased in septic shock rats compared with sham-operated rats. Conventional therapy, CsA, or PBA alone improved the contractility of CPM and SMA. And the combined administration of PBA and CsA significantly improved cardiovascular function. PBA &#x2b; CsA increased the maximal contraction of CPM and SMA to catecholamines by 29.18% and 16.28% and improved relaxation of SMA to acetylcholine by 37.29% (<xref ref-type="fig" rid="F3">Figures 3A&#x2013;C</xref>), compared with CsA alone. Besides, the cardiac output, cardiac index, and stroke index were significantly increased by CsA, PBA, and combined application, compared with LR. And the combination of CsA and PBA tended to demonstrate better therapeutic effects (<xref ref-type="fig" rid="F3">Figures 3D&#x2013;F</xref>).</p>
<fig id="F3" position="float">
<label>FIGURE 3</label>
<caption>
<p>Synergetic effect of PBA and CsA on improving cardiovascular function after septic shock in rats. (<italic>n</italic>&#x20;&#x3d; 8/group). <bold>(A)</bold>, the contractile response of cardiac papillary muscle (CPM) to ISO; <bold>(B)</bold>, contractile response superior mesenteric artery to NE; <bold>(C)</bold>, relaxation response of superior mesenteric artery to Ach; <bold>(D)</bold>, cardiac output (CO); <bold>(E)</bold>, cardiac index (CI); <bold>(F)</bold>, stroke index (SI). CsA, cyclosporine A; PBA, 4-phenylbutyrate acid; CT, conventional treatment; ISO, isoprenaline; NE, norepinephrine; Ach, acetylcholine. &#x2a;<italic>p</italic>&#x20;&#x3c; 0.05, &#x2a;&#x2a;<italic>p</italic>&#x20;&#x3c; 0.01, &#x2a;&#x2a;&#x2a;<italic>p</italic>&#x20;&#x3c; 0.001; <italic>ns</italic>, not significant.</p>
</caption>
<graphic xlink:href="fphar-12-770558-g003.tif"/>
</fig>
</sec>
<sec id="s3-2">
<title>Effects of Cyclosporine A and Phenylbutyric Acid on Mitochondrial Permeability Transition Pore and Endoplasmic Reticulum Stress in H9C2 cardiomyocytes and Vascular Smooth Muscle Cells after Septic Shock</title>
<p>In this part, we observed the changes of the protein level of adenine nucleotide translocase1 (ANT1), cyclophilin 40 (CypD), as well as voltage-dependent anion channel 1 (VDAC1), which were regarded as mPTP components and regulators. The results indicated that the expressions of ANT1, VDAC, and CypD were significantly increased in SMA and heart tissue after septic shock. (<xref ref-type="fig" rid="F4">Figures 4A&#x2013;H</xref>). LPS incubation (500&#xa0;ng/ml, 12&#xa0;h) caused significant mPTP opening in VSMCs and H9C2 cardiomyocytes, while betulinc acid (Betu), an mPTP opener, demonstrated comparable effects at 1&#xa0;&#x3bc;g/ml CsA (1&#xa0;&#x3bc;mol/L) and significantly reduced mPTP opening (<xref ref-type="fig" rid="F4">Figure&#x20;4I</xref>).</p>
<fig id="F4" position="float">
<label>FIGURE 4</label>
<caption>
<p>Effects of CsA on mPTP opening after septic shock in rats. <bold>(A-C)</bold>, expression of voltage-dependent anion channel (VDACs) and cyclophilin-D (CypD) and adenine nucleotide translocase (ANT) in the superior mesenteric artery (SMA) from septic-shock rats (<italic>n</italic>&#x20;&#x3d; 3); <bold>(E-H)</bold>, Expression of voltage-dependent anion channel (VDACs) and cyclophilin-D (CypD) and adenine nucleotide translocase (ANT) in the cardiac papillary muscle (CPM) from septic-shock rats (<italic>n</italic>&#x20;&#x3d; 3); <bold>(I-L)</bold>, mPTP opening in VSMCs and H9C2 cardiomyocytes (<italic>n</italic>&#x20;&#x3d; 20/group from 3 independent experiment). Scale bar &#x3d; 50&#xa0;&#x3bc;m. CLP, cecal ligation and puncture; CsA, cyclosporine A; Betu, betulinc acid; LPS, lipopolysaccharide; MFI, mean fluorescence intensity. &#x2a;<italic>p</italic>&#x20;&#x3c; 0.05, &#x2a;&#x2a;<italic>p</italic>&#x20;&#x3c; 0.01, &#x2a;&#x2a;&#x2a;<italic>p</italic>&#x20;&#x3c; 0.001; <italic>ns</italic>, not significant.</p>
</caption>
<graphic xlink:href="fphar-12-770558-g004.tif"/>
</fig>
<p>Besides, the expression of ERS-related proteins including C/EBP homologous protein (CHOP), glucose-regulated protein 78 (GRP78), and GRP94 in CLP-induced septic shock rats and LPS treated VSMCs and H9C2 cardiomyocytes were also investigated. Results showed the expression of CHOP was significantly increased in heart and&#x20;SMA tissues after CLP in rats in a time-dependent manner, whereas the expression of GRP78 and GRP94 did&#x20;not change significantly (<xref ref-type="fig" rid="F5">Figures 5A&#x2013;H</xref>). In VSMCs&#x20;and cardiomyocytes, LPS incubation at 500&#xa0;ng/ml increased CHOP expression significantly. Inhibition of ERS&#x20;with PBA (5&#xa0;&#x3bc;mol/L) abolished the LPS-induced increase in CHOP expression. LPS and PBA did not alter&#x20;the expression of GRP78 and GRP94 (<xref ref-type="fig" rid="F5">Figure 5I-P</xref>).&#x20;These results suggested the ERS and opening of mPTP&#x20;in H9C2 cardiomyocytes and VSMCs challenged with&#x20;LPS.</p>
<fig id="F5" position="float">
<label>FIGURE 5</label>
<caption>
<p>Effects of PBA on ERS-related protein expression after septic shock in rats. <bold>(A&#x2013;D)</bold>, Changes in expression of C/EBP homologous protein (CHOP), glucose-regulated protein 78 (GRP78), glucose-regulated protein 94 (GRP94) in the superior mesenteric artery after different times of CLP (<italic>n</italic>&#x20;&#x3d; 3); <bold>(E&#x2013;H)</bold>, Changes in expression of C/EBP homologous protein (CHOP), glucose-regulated protein 78 (GRP78), glucose-regulated protein 94 (GRP94) in the heart after different times of CLP (<italic>n</italic>&#x20;&#x3d; 3); <bold>(I&#x2013;L)</bold>, effects of anti-ERS with PBA on the expression of CHOP, GRP78, and GRP94 in LPS-challenged VSMCs; <bold>(M&#x2013;P)</bold>, effects of anti-ERS with PBA on the expression of CHOP, GRP78 and GRP94 in LPS-challenged H9C2 cardiomyocytes (<italic>n</italic>&#x20;&#x3d; 3). CLP, cecal ligation and puncture; CsA, cyclosporine A; PBA, 4-phenylbutyrate acid; &#x2a;&#x2a;<italic>p</italic>&#x20;&#x3c; 0.01, &#x2a;&#x2a;&#x2a;<italic>p</italic>&#x20;&#x3c; 0.001; <italic>ns</italic>, not significant.</p>
</caption>
<graphic xlink:href="fphar-12-770558-g005.tif"/>
</fig>
</sec>
<sec id="s3-3">
<title>Contribution of Phenylbutyric Acid in Cyclosporine A-Induced the Inhibition of Mitochondrial Permeability Transition Pore Opening After Septic Shock</title>
<p>To understand whether PBA affects mPTP opening after septic shock, the effects of PBA on mPTP opening were investigated in LPS-treated VSMCs and H9C2 cardiomyocytes. The results showed that treatment with PBA (5&#xa0;&#x3bc;mol/L, 4&#xa0;h) antagonized LPS-induced increases in expression of VDAC1, ANT1, CypD in VSMCs, and H9C2 cardiomyocytes (<xref ref-type="fig" rid="F6">Figures 6A&#x2013;J</xref>). Treatment with the ERS inhibitor PBA significantly reduced mPTP opening, and the fluorescence intensity of calcein was significantly increased compared with LPS treatment alone (<xref ref-type="fig" rid="F6">Figure&#x20;6K-N</xref>).</p>
<fig id="F6" position="float">
<label>FIGURE 6</label>
<caption>
<p>Effects of ERS on mPTP opening and its related protein expression after septic shock in rats in LPS-treated VSMCs and H9C2 cardiomyocytes. <bold>(A)</bold>, effects of CHOP RNAi on CHOP expression in VSMCs; <bold>(B-E)</bold>, effects of anti-ERS with PBA and CHOP-RNAi on the expression of mPTP-related proteins ANT, VDACs and CypD in VSMCs (<italic>n</italic>&#x20;&#x3d; 3); f, effects of CHOP RNAi on CHOP expression in H9C2 cardiomyocytes; <bold>(G-J)</bold>, effects of anti-ERS with PBA and CHOP-RNAi on the expression of mPTP-related proteins ANT, VDACs and CypD H9C2 cardiomyocytes (<italic>n</italic>&#x20;&#x3d; 3); <bold>(K,M)</bold>, effects of anti-ERS with PBA and CHOP-RNAi on mPTP opening in LPS-challenged VSMCs (<italic>n</italic>&#x20;&#x3d; 21/group from 3 independent experiment); <bold>(L,N)</bold>, effects of anti-ERS with PBA and CHOP-RNAi on mPTP opening in LPS-challenged H9C2 cardiomyocytes (<italic>n</italic>&#x20;&#x3d; 21/group from 3 independent experiment); <bold>(O)</bold>, schematic of synergetic effect of PBA and CsA protecting vascular function and benefiting to sepsis. Scale bar &#x3d; 50&#xa0;&#x3bc;m. CsA, cyclosporine A; PBA, 4-phenylbutyrate acid; MFI, mean fluorescence intensity. &#x2a;<italic>p</italic>&#x20;&#x3c; 0.05, &#x2a;&#x2a;<italic>p</italic>&#x20;&#x3c; 0.01, &#x2a;&#x2a;&#x2a;<italic>p</italic>&#x20;&#x3c; 0.001; <italic>ns</italic>, not significant.</p>
</caption>
<graphic xlink:href="fphar-12-770558-g006.tif"/>
</fig>
<p>The above study found that expression of CHOP was significantly increased after sepsis and PBA administration decreased the expression of CHOP. To further explore the relationship of ERS and mPTP opening, the effect of inhibition of CHOP (by transfection of its siRNA) on mPTP opening in VSMCs and H9C2 cardiomyocytes was observed. The results showed that interference of CHOP with its siRNA significantly inhibited the expression of CypD and ANT in VSMCs and H9C2 cardiomyocytes. Meanwhile, CHOP RNAi antagonized LPS-induced mPTP opening, too. The results further proved the close relationship between ERS and mPTP opening.</p>
</sec>
</sec>
<sec sec-type="discussion" id="s4">
<title>Discussion</title>
<p>This study showed that inhibition of the mPTP opening with CsA or anti-ERS with PBA could improve cardiovascular function, increase the blood flow of vital organs, and increase the delivery and utilization of oxygen, and improve the survival in septic rats. The combination of PBA with CsA significantly enhanced the beneficial effects of CsA or PBA on both heart and blood vessels following septic shock. PBA enforced CsA-induced cardiovascular protection contributed the synergetic effect on sepsis treatment. The results indicated that PBA &#x2b; CsA may be a perspective treatment for protecting cardiovascular function in sepsis or septic&#x20;shock.</p>
<p>Despite the many efforts made for the treatment of sepsis or septic shock, the morbidity and mortality of severe sepsis and septic shock remained high. New therapeutic targets for sepsis have been proposed in recent years: protecting the glycocalyx, antioxidant (<xref ref-type="bibr" rid="B29">Uchimido et&#x20;al., 2019</xref>), stimulating immune function, as well as blocking of cytokine storm (<xref ref-type="bibr" rid="B28">Tanaka et&#x20;al., 2016</xref>; <xref ref-type="bibr" rid="B31">Venet and Monneret, 2018</xref>). However, searching for novel therapies is still important for reducing the mortality of sepsis or septic shock. This study found that inhibiting mPTP opening with CsA could decrease the morbidity of septic shock and increase animal survival in CLP-induced septic shock rats. Combining anti-ERS with PBA enforced the beneficial effects of CsA on septic shock rats, which suggested that anti-mPTP opening in combination with anti-ERS might be more effective strategy for the treatment of severe sepsis or septic&#x20;shock.</p>
<p>In this study, we found that CsA benefited sepsis via inhibiting mPTP opening. CsA could interact with the hydrophobic pocket of CypD and inhibit PPIase activity of CypD and reduce mPTP opening. Besides, CsA would interact with CypD already bound to the ATP synthase and thereby protect mitochondria (<xref ref-type="bibr" rid="B1">Amanakis et&#x20;al., 2020</xref>). What other mechanisms participate in the protective role of CsA in sepsis needs further investigation. For example, there were studies that showed that CsA was beneficial to impaired myocardial function following sepsis by blocking mitochondrial cytochrome c release and regulating calcineurin to mediate mitochondrial respiration and reduce tissue nitration and protein carbonylation (<xref ref-type="bibr" rid="B7">Fauvel et&#x20;al., 2002</xref>; <xref ref-type="bibr" rid="B12">Joshi et&#x20;al., 2006</xref>). CsA forms a complex with cytosolic cyclophilin-A that inhibits the calcium-activated protein phosphatase calcineurin, and through this pathway, the immune-suppressive effects were promoted (<xref ref-type="bibr" rid="B26">Schreiber and Crabtree, 1992</xref>) and CsA was commonly used in the clinic for the organ transplants and immunoregulation. Thus, the therapeutic application of CsA as a desensitizer of the mPTP has been hindered for many years. In our pilot study, five CsA doses (0.05, 1, 5, 10, 20&#xa0;mg/kg) were applied; 5&#xa0;mg/kg had better effects to inhibit mPTP opening, but whether 5&#xa0;mg/kg CsA demonstrated immunosuppression, and whether PBA can inhibit or alleviate CsA-induced immune-suppression, is not known. And for the important role of mPTP in the progress of many diseases, several mPTP inhibitors have been developed for more cardiovascular protection and less adverse effects, such as sanglifehrin A, 6-MeAla-CsA, 4-methyl-val-CsA, N-methyl-4-isoleucine-CsA (NIM811), and D-3-MeAla-4-EtVal-CsA (Debio-025) and so on (<xref ref-type="bibr" rid="B4">Clarke et&#x20;al., 2002</xref>; <xref ref-type="bibr" rid="B9">Hausenloy et&#x20;al., 2003</xref>). Whether these compounds demonstrate immunosuppression effects and benefit sepsis remains to be explored.</p>
<p>The mPTP was opened in VSMCs and H9C2 cardiomyocytes after septic shock or stimulation with LPS. Several factors may lead to the opening of mPTP. Ca<sup>2&#x2b;</sup> overload in mitochondria, increases in oxidative stress, as well as depletion of adenosine triphosphate could result in the opening of mPTP. The endoplasmic reticulum and mitochondria are closely connected physically and functionally, Miki et&#x20;al. noted that ERS in diabetic hearts impairs phosphoglycogen synthase kinase-3&#x3b2;-mediated suppression of mPTP opening (<xref ref-type="bibr" rid="B22">Miki et&#x20;al., 2009</xref>; <xref ref-type="bibr" rid="B2">Belaidi et&#x20;al., 2013</xref>). In this study, ERS also contributed to&#x20;mPTP opening after septic shock. We found ERS in cardiac muscle and vascular smooth muscle after septic shock, indicated by the increase of CHOP expression in VSMCs and H9C2 cardiomyocytes after CLP or LPS stimulation. Inhibition of ERS with PBA prevented mPTP opening. Downregulation of CHOP by its RNAi antagonized LPS-induced mPTP opening as well as the increase in the expression of ANT and CypD. These results suggested that septic shock-induced ERS contributed to mPTP opening, and CHOP is the important molecule participating in this process.</p>
<p>PBA is an orally bioavailable terminal aromatic substituted fatty acid that is used in the treatment of various metabolic diseases, including cancer, genetic metabolic syndromes, neuropathies, diabetes, hemoglobinopathies, and urea cycle disorders. The mechanisms are varied. In general, PBA plays the role of an HDAC inhibitor or as a chemical chaperone rescuing conformational abnormalities of protein, and thus may help to reduce unfolded protein reaction and the ERS (<xref ref-type="bibr" rid="B14">Kusaczuk et&#x20;al., 2015</xref>; <xref ref-type="bibr" rid="B10">He and Moreau, 2019</xref>). Previous studies reported that ERS act upstream of mPTP opening and thus in this study we investigated the effects of inhibition of ERS on mPTP opening. However, CsA was also reported to induce ERS vice versa (<xref ref-type="bibr" rid="B25">Rao et&#x20;al., 2017</xref>). The mechanism of the synergetic effect might be explained as follows: a, PBA reduced the side effect of CsA and enhanced mPTP inhibiting; b, PBA reduced CypD expression through inhibiting ERS and CHOP (<xref ref-type="fig" rid="F6">Figure&#x20;6O</xref>).</p>
<p>There might be other mechanisms that PBA enhanced the function of CsA, and we think nitric oxide (NO) might play a role. In severe sepsis, the content of plasma nitric oxide is significantly increased, and excessive nitric oxide could lead to impaired mitochondrial respiration (<xref ref-type="bibr" rid="B32">Vico et&#x20;al., 2019</xref>) and mPTP opening in the heart (<xref ref-type="bibr" rid="B6">Dynnik et&#x20;al., 2020</xref>). PBA was able to activate eNOS, increase NO level, and activate the mitochondrial mtNOS-SS system to inhibit mPTP opening (<xref ref-type="bibr" rid="B6">Dynnik et&#x20;al., 2020</xref>). Increased NO level also improved the protective effect of CsA in the ischemia/reperfusion heart (<xref ref-type="bibr" rid="B8">Gross et&#x20;al., 2013</xref>). These studies implied that the combination of PBA and CsA might benefit sepsis through NO, rather than just inhibiting ER stress.</p>
<p>In this study, the 72&#x20;h survival rate in the conventional treatment group was indeed similar to that in the untreated group. According to the guidelines for sepsis treatment, we administrated fluid resuscitation combined with antibiotics and vasoactive drugs for severe sepsis rats. At 6&#xa0;h after treatment, 7/16 of the CT group survived, while only 3/16 of the untreated group survived, indicating that the conventional treatment was effective in the initial stage of treatment but advanced organ function protection measures were needed to further prolong the survival time. Our study has some limitations. Firstly, the effect of PBA on immunosuppression and kidney toxicity by CsA was unexplored. Secondly, although we found that ERS took part in the regulation of mPTP opening after septic shock, and CHOP may be the main molecule in this process, how CHOP regulates mPTP opening needs further investigation.</p>
</sec>
<sec sec-type="conclusion" id="s5">
<title>Conclusion</title>
<p>The combined application of PBA and CsA produced synergetic protection against severe sepsis via improving cardiovascular function. The mechanism is closely related to PBA enforcing the inhibitory effect of CsA on mitochondrial permeability transition pore and reducing the side effect of&#x20;CsA.</p>
</sec>
</body>
<back>
<sec id="s6">
<title>Data Availability Statement</title>
<p>The original contributions presented in the study are included in the article/<xref ref-type="sec" rid="s12">Supplementary Material</xref>, further inquiries can be directed to the corresponding author.</p>
</sec>
<sec id="s7">
<title>Ethics Statement</title>
<p>The animal study was reviewed and approved by Laboratory Animal Welfare and Ethics Committee of Third Military Medical University (Army Medical University).</p>
</sec>
<sec id="s8">
<title>Author Contributions</title>
<p>KL, ZY, WY, PX, TK performed the experiment; KL analyzed the data and drafted the manuscript; LL and LT designed the experiment, revised the manuscript and obtained the funding. All authors approved the work for publication.</p>
</sec>
<sec id="s9">
<title>Funding</title>
<p>This study was supported by the National Natural Science Foundation of China (81730059) and Talent Training Program of Army Medical University (B-3222). The funding agencies had no role in study design, collection and analyses of data, decision to publish, or preparation of the manuscript.</p>
</sec>
<sec sec-type="COI-statement" id="s10">
<title>Conflict of Interest</title>
<p>The authors declare that the research was conducted in the absence of any commercial or financial relationships that could be construed as a potential conflict of interest.</p>
</sec>
<sec sec-type="disclaimer" id="s11">
<title>Publisher&#x2019;s Note</title>
<p>All claims expressed in this article are solely those of the authors and do not necessarily represent those of their affiliated organizations, or those of the publisher, the editors, and the reviewers. Any product that may be evaluated in this article, or claim that may be made by its manufacturer, is not guaranteed or endorsed by the publisher.</p>
</sec>
<ack>
<p>We thank JZ, JZ, and XX from our lab for their kind help in the animal model establishment and data collection.</p>
</ack>
<sec id="s12">
<title>Supplementary Material</title>
<p>The Supplementary Material for this article can be found online at: <ext-link ext-link-type="uri" xlink:href="https://www.frontiersin.org/articles/10.3389/fphar.2021.770558/full#supplementary-material">https://www.frontiersin.org/articles/10.3389/fphar.2021.770558/full&#x23;supplementary-material</ext-link>
</p>
<supplementary-material xlink:href="DataSheet1.xlsx" id="SM1" mimetype="application/xlsx" xmlns:xlink="http://www.w3.org/1999/xlink"/>
</sec>
<ref-list>
<title>References</title>
<ref id="B1">
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Amanakis</surname>
<given-names>G.</given-names>
</name>
<name>
<surname>Murphy</surname>
<given-names>E.</given-names>
</name>
<name>
<surname>Cyclophilin</surname>
<given-names>D.</given-names>
</name>
</person-group> (<year>2020</year>). <article-title>Cyclophilin D: An Integrator of Mitochondrial Function</article-title>. <source>Front. Physiol.</source> <volume>11</volume>, <fpage>595</fpage>. <pub-id pub-id-type="doi">10.3389/fphys.2020.00595</pub-id> </citation>
</ref>
<ref id="B2">
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Belaidi</surname>
<given-names>E.</given-names>
</name>
<name>
<surname>Decorps</surname>
<given-names>J.</given-names>
</name>
<name>
<surname>Augeul</surname>
<given-names>L.</given-names>
</name>
<name>
<surname>Durand</surname>
<given-names>A.</given-names>
</name>
<name>
<surname>Ovize</surname>
<given-names>M.</given-names>
</name>
</person-group> (<year>2013</year>). <article-title>Endoplasmic Reticulum Stress Contributes to Heart protection Induced by Cyclophilin D Inhibition</article-title>. <source>Basic Res. Cardiol.</source> <volume>108</volume> (<issue>4</issue>), <fpage>363</fpage>. <pub-id pub-id-type="doi">10.1007/s00395-013-0363-z</pub-id> </citation>
</ref>
<ref id="B3">
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Cecconi</surname>
<given-names>M.</given-names>
</name>
<name>
<surname>Evans</surname>
<given-names>L.</given-names>
</name>
<name>
<surname>Levy</surname>
<given-names>M.</given-names>
</name>
<name>
<surname>Rhodes</surname>
<given-names>A.</given-names>
</name>
</person-group> (<year>2018</year>). <article-title>Sepsis and Septic Shock</article-title>. <source>Lancet</source> <volume>392</volume> (<issue>10141</issue>), <fpage>75</fpage>&#x2013;<lpage>87</lpage>. <pub-id pub-id-type="doi">10.1016/S0140-6736(18)30696-2</pub-id> </citation>
</ref>
<ref id="B4">
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Clarke</surname>
<given-names>S. J.</given-names>
</name>
<name>
<surname>McStay</surname>
<given-names>G. P.</given-names>
</name>
<name>
<surname>Halestrap</surname>
<given-names>A. P.</given-names>
</name>
</person-group> (<year>2002</year>). <article-title>Sanglifehrin A Acts as a Potent Inhibitor of the Mitochondrial Permeability Transition and Reperfusion Injury of the Heart by Binding to Cyclophilin-D at a Different Site from Cyclosporin A</article-title>. <source>J.&#x20;Biol. Chem.</source> <volume>277</volume> (<issue>38</issue>), <fpage>34793</fpage>&#x2013;<lpage>34799</lpage>. <pub-id pub-id-type="doi">10.1074/jbc.M202191200</pub-id> </citation>
</ref>
<ref id="B5">
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Duan</surname>
<given-names>C.</given-names>
</name>
<name>
<surname>Kuang</surname>
<given-names>L.</given-names>
</name>
<name>
<surname>Xiang</surname>
<given-names>X.</given-names>
</name>
<name>
<surname>Zhang</surname>
<given-names>J.</given-names>
</name>
<name>
<surname>Zhu</surname>
<given-names>Y.</given-names>
</name>
<name>
<surname>Wu</surname>
<given-names>Y.</given-names>
</name>
<etal/>
</person-group> (<year>2020</year>). <article-title>Drp1 Regulates Mitochondrial Dysfunction and Dysregulated Metabolism in Ischemic Injury via Clec16a-, BAX-, and GSH- Pathways</article-title>. <source>Cell Death Dis</source> <volume>11</volume> (<issue>4</issue>), <fpage>251</fpage>. <pub-id pub-id-type="doi">10.1038/s41419-020-2461-9</pub-id> </citation>
</ref>
<ref id="B6">
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Dynnik</surname>
<given-names>V. V.</given-names>
</name>
<name>
<surname>Grishina</surname>
<given-names>E. V.</given-names>
</name>
<name>
<surname>Fedotcheva</surname>
<given-names>N. I.</given-names>
</name>
</person-group> (<year>2020</year>). <article-title>The Mitochondrial NO-Synthase/guanylate Cyclase/protein Kinase G Signaling System Underpins the Dual Effects of Nitric Oxide on Mitochondrial Respiration and Opening of the Permeability Transition Pore</article-title>. <source>FEBS J.</source> <volume>287</volume> (<issue>8</issue>), <fpage>1525</fpage>&#x2013;<lpage>1536</lpage>. <pub-id pub-id-type="doi">10.1111/febs.15090</pub-id> </citation>
</ref>
<ref id="B7">
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Fauvel</surname>
<given-names>H.</given-names>
</name>
<name>
<surname>Marchetti</surname>
<given-names>P.</given-names>
</name>
<name>
<surname>Obert</surname>
<given-names>G.</given-names>
</name>
<name>
<surname>Joulain</surname>
<given-names>O.</given-names>
</name>
<name>
<surname>Chopin</surname>
<given-names>C.</given-names>
</name>
<name>
<surname>Formstecher</surname>
<given-names>P.</given-names>
</name>
<etal/>
</person-group> (<year>2002</year>). <article-title>Protective Effects of Cyclosporin A from Endotoxin-Induced Myocardial Dysfunction and Apoptosis in Rats</article-title>. <source>Am. J.&#x20;Respir. Crit. Care Med.</source> <volume>165</volume> (<issue>4</issue>), <fpage>449</fpage>&#x2013;<lpage>455</lpage>. <pub-id pub-id-type="doi">10.1164/ajrccm.165.4.2105084</pub-id> </citation>
</ref>
<ref id="B8">
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Gross</surname>
<given-names>G. J.</given-names>
</name>
<name>
<surname>Hsu</surname>
<given-names>A.</given-names>
</name>
<name>
<surname>Pfeiffer</surname>
<given-names>A. W.</given-names>
</name>
<name>
<surname>Nithipatikom</surname>
<given-names>K.</given-names>
</name>
</person-group> (<year>2013</year>). <article-title>Roles of Endothelial Nitric Oxide Synthase (eNOS) and Mitochondrial Permeability Transition Pore (MPTP) in Epoxyeicosatrienoic Acid (EET)-induced Cardioprotection against Infarction in Intact Rat Hearts</article-title>. <source>J.&#x20;Mol. Cel Cardiol</source> <volume>59</volume>, <fpage>20</fpage>&#x2013;<lpage>29</lpage>. <pub-id pub-id-type="doi">10.1016/j.yjmcc.2013.02.003</pub-id> </citation>
</ref>
<ref id="B9">
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Hausenloy</surname>
<given-names>D. J.</given-names>
</name>
<name>
<surname>Duchen</surname>
<given-names>M. R.</given-names>
</name>
<name>
<surname>Yellon</surname>
<given-names>D. M.</given-names>
</name>
</person-group> (<year>2003</year>). <article-title>Inhibiting Mitochondrial Permeability Transition Pore Opening at Reperfusion Protects against Ischaemia-Reperfusion Injury</article-title>. <source>Cardiovasc. Res.</source> <volume>60</volume> (<issue>3</issue>), <fpage>617</fpage>&#x2013;<lpage>625</lpage>. <pub-id pub-id-type="doi">10.1016/j.cardiores.2003.09.025</pub-id> </citation>
</ref>
<ref id="B10">
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>He</surname>
<given-names>B.</given-names>
</name>
<name>
<surname>Moreau</surname>
<given-names>R.</given-names>
</name>
</person-group> (<year>2019</year>). <article-title>Lipid-regulating Properties of Butyric Acid and 4-phenylbutyric Acid: Molecular Mechanisms and Therapeutic Applications</article-title>. <source>Pharmacol. Res.</source> <volume>144</volume>, <fpage>116</fpage>&#x2013;<lpage>131</lpage>. <pub-id pub-id-type="doi">10.1016/j.phrs.2019.04.002</pub-id> </citation>
</ref>
<ref id="B11">
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Hong</surname>
<given-names>J.</given-names>
</name>
<name>
<surname>Kim</surname>
<given-names>K.</given-names>
</name>
<name>
<surname>Kim</surname>
<given-names>J.&#x20;H.</given-names>
</name>
<name>
<surname>Park</surname>
<given-names>Y.</given-names>
</name>
</person-group> (<year>2017</year>). <article-title>The Role of Endoplasmic Reticulum Stress in Cardiovascular Disease and Exercise</article-title>. <source>Int. J.&#x20;Vasc. Med.</source> <volume>2017</volume>, <fpage>2049217</fpage>. <pub-id pub-id-type="doi">10.1155/2017/2049217</pub-id> </citation>
</ref>
<ref id="B12">
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Joshi</surname>
<given-names>M. S.</given-names>
</name>
<name>
<surname>Julian</surname>
<given-names>M. W.</given-names>
</name>
<name>
<surname>Huff</surname>
<given-names>J.&#x20;E.</given-names>
</name>
<name>
<surname>Bauer</surname>
<given-names>J.&#x20;A.</given-names>
</name>
<name>
<surname>Xia</surname>
<given-names>Y.</given-names>
</name>
<name>
<surname>Crouser</surname>
<given-names>E. D.</given-names>
</name>
</person-group> (<year>2006</year>). <article-title>Calcineurin Regulates Myocardial Function during Acute Endotoxemia</article-title>. <source>Am. J.&#x20;Respir. Crit. Care Med.</source> <volume>173</volume> (<issue>9</issue>), <fpage>999</fpage>&#x2013;<lpage>1007</lpage>. <pub-id pub-id-type="doi">10.1164/rccm.200411-1507OC</pub-id> </citation>
</ref>
<ref id="B13">
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Khan</surname>
<given-names>M. M.</given-names>
</name>
<name>
<surname>Yang</surname>
<given-names>W. L.</given-names>
</name>
<name>
<surname>Wang</surname>
<given-names>P.</given-names>
</name>
</person-group> (<year>2015</year>). <article-title>Endoplasmic Reticulum Stress in Sepsis</article-title>. <source>Shock</source> <volume>44</volume> (<issue>4</issue>), <fpage>294</fpage>&#x2013;<lpage>304</lpage>. <pub-id pub-id-type="doi">10.1097/SHK.0000000000000425</pub-id> </citation>
</ref>
<ref id="B14">
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Kusaczuk</surname>
<given-names>M.</given-names>
</name>
<name>
<surname>Bartoszewicz</surname>
<given-names>M.</given-names>
</name>
<name>
<surname>Cechowska-Pasko</surname>
<given-names>M.</given-names>
</name>
</person-group> (<year>2015</year>). <article-title>Phenylbutyric Acid: Simple Structure - Multiple Effects</article-title>. <source>Curr. Pharm. Des.</source> <volume>21</volume> (<issue>16</issue>), <fpage>2147</fpage>&#x2013;<lpage>2166</lpage>. <pub-id pub-id-type="doi">10.2174/1381612821666150105160059</pub-id> </citation>
</ref>
<ref id="B15">
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Leung</surname>
<given-names>A. W.</given-names>
</name>
<name>
<surname>Halestrap</surname>
<given-names>A. P.</given-names>
</name>
</person-group> (<year>2008</year>). <article-title>Recent Progress in Elucidating the&#x20;Molecular Mechanism of the Mitochondrial Permeability Transition Pore</article-title>. <source>Biochim. Biophys. Acta</source> <volume>1777</volume> (<issue>7-8</issue>), <fpage>946</fpage>&#x2013;<lpage>952</lpage>. <pub-id pub-id-type="doi">10.1016/j.bbabio.2008.03.009</pub-id> </citation>
</ref>
<ref id="B16">
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Li</surname>
<given-names>T.</given-names>
</name>
<name>
<surname>Fang</surname>
<given-names>Y.</given-names>
</name>
<name>
<surname>Yang</surname>
<given-names>G.</given-names>
</name>
<name>
<surname>Xu</surname>
<given-names>J.</given-names>
</name>
<name>
<surname>Zhu</surname>
<given-names>Y.</given-names>
</name>
<name>
<surname>Liu</surname>
<given-names>L.</given-names>
</name>
</person-group> (<year>2011</year>). <article-title>Effects of the Balance in Activity of RhoA and Rac1 on the Shock-Induced Biphasic Change of Vascular Reactivity in Rats</article-title>. <source>Ann. Surg.</source> <volume>253</volume> (<issue>1</issue>), <fpage>185</fpage>&#x2013;<lpage>193</lpage>. <pub-id pub-id-type="doi">10.1097/SLA.0b013e3181f9b88b</pub-id> </citation>
</ref>
<ref id="B17">
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Li</surname>
<given-names>T.</given-names>
</name>
<name>
<surname>Fang</surname>
<given-names>Y.</given-names>
</name>
<name>
<surname>Yang</surname>
<given-names>G.</given-names>
</name>
<name>
<surname>Zhu</surname>
<given-names>Y.</given-names>
</name>
<name>
<surname>Xu</surname>
<given-names>J.</given-names>
</name>
<name>
<surname>Liu</surname>
<given-names>L.</given-names>
</name>
</person-group> (<year>2010</year>). <article-title>The Mechanism by Which RhoA Regulates Vascular Reactivity after Hemorrhagic Shock in Rats</article-title>. <source>Am. J.&#x20;Physiol. Heart Circ. Physiol.</source> <volume>299</volume> (<issue>2</issue>), <fpage>H292</fpage>&#x2013;<lpage>H299</lpage>. <pub-id pub-id-type="doi">10.1152/ajpheart.01031.2009</pub-id> </citation>
</ref>
<ref id="B18">
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Li</surname>
<given-names>T.</given-names>
</name>
<name>
<surname>Fang</surname>
<given-names>Y.</given-names>
</name>
<name>
<surname>Zhu</surname>
<given-names>Y.</given-names>
</name>
<name>
<surname>Fan</surname>
<given-names>X.</given-names>
</name>
<name>
<surname>Liao</surname>
<given-names>Z.</given-names>
</name>
<name>
<surname>Chen</surname>
<given-names>F.</given-names>
</name>
<etal/>
</person-group> (<year>2011</year>). <article-title>A Small Dose of Arginine Vasopressin in Combination with Norepinephrine Is a Good Early Treatment for Uncontrolled Hemorrhagic Shock after Hemostasis</article-title>. <source>J.&#x20;Surg. Res.</source> <volume>169</volume> (<issue>1</issue>), <fpage>76</fpage>&#x2013;<lpage>84</lpage>. <pub-id pub-id-type="doi">10.1016/j.jss.2010.02.001</pub-id> </citation>
</ref>
<ref id="B19">
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Li</surname>
<given-names>T.</given-names>
</name>
<name>
<surname>Zhu</surname>
<given-names>Y.</given-names>
</name>
<name>
<surname>Liu</surname>
<given-names>L.</given-names>
</name>
</person-group> (<year>2010</year>). <article-title>Role of Rho Kinase in the Dysfunction of Myocardium Contraction in Hemorrhagic Shock Rats</article-title>. <source>Chin. J.&#x20;Pathophysiol.</source> <volume>26</volume>, <fpage>1059</fpage>&#x2013;<lpage>1063</lpage>. <pub-id pub-id-type="doi">10.3969/j.issn.1000-4718.2010.06.004</pub-id> </citation>
</ref>
<ref id="B20">
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Li</surname>
<given-names>T.</given-names>
</name>
<name>
<surname>Zhu</surname>
<given-names>Y.</given-names>
</name>
<name>
<surname>Tian</surname>
<given-names>K.</given-names>
</name>
<name>
<surname>Xue</surname>
<given-names>M.</given-names>
</name>
<name>
<surname>Peng</surname>
<given-names>X.</given-names>
</name>
<name>
<surname>Lan</surname>
<given-names>D.</given-names>
</name>
<etal/>
</person-group> (<year>2013</year>). <article-title>Ideal Resuscitation Pressure for Uncontrolled Hemorrhagic Shock in Different Ages and Sexes of Rats</article-title>. <source>Crit. Care</source> <volume>17</volume> (<issue>5</issue>), <fpage>R194</fpage>. <pub-id pub-id-type="doi">10.1186/cc12888</pub-id> </citation>
</ref>
<ref id="B21">
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Liu</surname>
<given-names>L.</given-names>
</name>
<name>
<surname>Wu</surname>
<given-names>H.</given-names>
</name>
<name>
<surname>Zang</surname>
<given-names>J.</given-names>
</name>
<name>
<surname>Yang</surname>
<given-names>G.</given-names>
</name>
<name>
<surname>Zhu</surname>
<given-names>Y.</given-names>
</name>
<name>
<surname>Wu</surname>
<given-names>Y.</given-names>
</name>
<etal/>
</person-group> (<year>2016</year>). <article-title>4-Phenylbutyric Acid Reveals Good Beneficial Effects on Vital Organ Function via Anti-endoplasmic Reticulum Stress in Septic Rats</article-title>. <source>Crit. Care Med.</source> <volume>44</volume> (<issue>8</issue>), <fpage>e689</fpage>&#x2013;<lpage>701</lpage>. <pub-id pub-id-type="doi">10.1097/CCM.0000000000001662</pub-id> </citation>
</ref>
<ref id="B22">
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Miki</surname>
<given-names>T.</given-names>
</name>
<name>
<surname>Miura</surname>
<given-names>T.</given-names>
</name>
<name>
<surname>Hotta</surname>
<given-names>H.</given-names>
</name>
<name>
<surname>Tanno</surname>
<given-names>M.</given-names>
</name>
<name>
<surname>Yano</surname>
<given-names>T.</given-names>
</name>
<name>
<surname>Sato</surname>
<given-names>T.</given-names>
</name>
<etal/>
</person-group> (<year>2009</year>). <article-title>Endoplasmic Reticulum Stress in Diabetic Hearts Abolishes Erythropoietin-Induced Myocardial protection by Impairment of Phospho-Glycogen Synthase Kinase-3beta-Mediated Suppression of Mitochondrial Permeability Transition</article-title>. <source>Diabetes</source> <volume>58</volume> (<issue>12</issue>), <fpage>2863</fpage>&#x2013;<lpage>2872</lpage>. <pub-id pub-id-type="doi">10.2337/db09-0158</pub-id> </citation>
</ref>
<ref id="B23">
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Morciano</surname>
<given-names>G.</given-names>
</name>
<name>
<surname>Bonora</surname>
<given-names>M.</given-names>
</name>
<name>
<surname>Campo</surname>
<given-names>G.</given-names>
</name>
<name>
<surname>Aquila</surname>
<given-names>G.</given-names>
</name>
<name>
<surname>Rizzo</surname>
<given-names>P.</given-names>
</name>
<name>
<surname>Giorgi</surname>
<given-names>C.</given-names>
</name>
<etal/>
</person-group> (<year>2017</year>). <article-title>Mechanistic Role of mPTP in Ischemia-Reperfusion Injury</article-title>. <source>Adv. Exp. Med. Biol.</source> <volume>982</volume>, <fpage>169</fpage>&#x2013;<lpage>189</lpage>. <pub-id pub-id-type="doi">10.1007/978-3-319-55330-6_9</pub-id> </citation>
</ref>
<ref id="B24">
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Pool</surname>
<given-names>R.</given-names>
</name>
<name>
<surname>Gomez</surname>
<given-names>H.</given-names>
</name>
<name>
<surname>Kellum</surname>
<given-names>J.&#x20;A.</given-names>
</name>
</person-group> (<year>2018</year>). <article-title>Mechanisms of Organ Dysfunction in Sepsis</article-title>. <source>Crit. Care Clin.</source> <volume>34</volume> (<issue>1</issue>), <fpage>63</fpage>&#x2013;<lpage>80</lpage>. <pub-id pub-id-type="doi">10.1016/j.ccc.2017.08.003</pub-id> </citation>
</ref>
<ref id="B25">
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Rao</surname>
<given-names>S. R.</given-names>
</name>
<name>
<surname>Sundararajan</surname>
<given-names>S.</given-names>
</name>
<name>
<surname>Subbarayan</surname>
<given-names>R.</given-names>
</name>
<name>
<surname>Murugan Girija</surname>
<given-names>D.</given-names>
</name>
</person-group> (<year>2017</year>). <article-title>Cyclosporine-A Induces Endoplasmic Reticulum Stress and Influences Pro-apoptotic Factors in Human Gingival Fibroblasts</article-title>. <source>Mol. Cel Biochem</source> <volume>429</volume> (<issue>1-2</issue>), <fpage>179</fpage>&#x2013;<lpage>185</lpage>. <pub-id pub-id-type="doi">10.1007/s11010-017-2945-9</pub-id> </citation>
</ref>
<ref id="B26">
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Schreiber</surname>
<given-names>S. L.</given-names>
</name>
<name>
<surname>Crabtree</surname>
<given-names>G. R.</given-names>
</name>
</person-group> (<year>1992</year>). <article-title>The Mechanism of Action of Cyclosporin A and FK506</article-title>. <source>Immunol. Today</source> <volume>13</volume> (<issue>4</issue>), <fpage>136</fpage>&#x2013;<lpage>142</lpage>. <pub-id pub-id-type="doi">10.1016/0167-5699(92)90111-J</pub-id> </citation>
</ref>
<ref id="B27">
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Supinski</surname>
<given-names>G. S.</given-names>
</name>
<name>
<surname>Schroder</surname>
<given-names>E. A.</given-names>
</name>
<name>
<surname>Callahan</surname>
<given-names>L. A.</given-names>
</name>
</person-group> (<year>2020</year>). <article-title>Mitochondria and Critical Illness</article-title>. <source>Chest</source> <volume>157</volume> (<issue>2</issue>), <fpage>310</fpage>&#x2013;<lpage>322</lpage>. <pub-id pub-id-type="doi">10.1016/j.chest.2019.08.2182</pub-id> </citation>
</ref>
<ref id="B28">
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Tanaka</surname>
<given-names>T.</given-names>
</name>
<name>
<surname>Narazaki</surname>
<given-names>M.</given-names>
</name>
<name>
<surname>Kishimoto</surname>
<given-names>T.</given-names>
</name>
</person-group> (<year>2016</year>). <article-title>Immunotherapeutic Implications of IL-6 Blockade for Cytokine Storm</article-title>. <source>Immunotherapy</source> <volume>8</volume> (<issue>8</issue>), <fpage>959</fpage>&#x2013;<lpage>970</lpage>. <pub-id pub-id-type="doi">10.2217/imt-2016-0020</pub-id> </citation>
</ref>
<ref id="B29">
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Uchimido</surname>
<given-names>R.</given-names>
</name>
<name>
<surname>Schmidt</surname>
<given-names>E. P.</given-names>
</name>
<name>
<surname>Shapiro</surname>
<given-names>N. I.</given-names>
</name>
</person-group> (<year>2019</year>). <article-title>The Glycocalyx: a Novel Diagnostic and Therapeutic Target in Sepsis</article-title>. <source>Crit. Care</source> <volume>23</volume> (<issue>1</issue>), <fpage>16</fpage>. <pub-id pub-id-type="doi">10.1186/s13054-018-2292-6</pub-id> </citation>
</ref>
<ref id="B30">
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>van Gurp</surname>
<given-names>M.</given-names>
</name>
<name>
<surname>Festjens</surname>
<given-names>N.</given-names>
</name>
<name>
<surname>van Loo</surname>
<given-names>G.</given-names>
</name>
<name>
<surname>Saelens</surname>
<given-names>X.</given-names>
</name>
<name>
<surname>Vandenabeele</surname>
<given-names>P.</given-names>
</name>
</person-group> (<year>2003</year>). <article-title>Mitochondrial Intermembrane Proteins in Cell Death</article-title>. <source>Biochem. Biophys. Res. Commun.</source> <volume>304</volume> (<issue>3</issue>), <fpage>487</fpage>&#x2013;<lpage>497</lpage>. <pub-id pub-id-type="doi">10.1016/s0006-291x(03)00621-1</pub-id> </citation>
</ref>
<ref id="B31">
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Venet</surname>
<given-names>F.</given-names>
</name>
<name>
<surname>Monneret</surname>
<given-names>G.</given-names>
</name>
</person-group> (<year>2018</year>). <article-title>Advances in the Understanding and Treatment of Sepsis-Induced Immunosuppression</article-title>. <source>Nat. Rev. Nephrol.</source> <volume>14</volume> (<issue>2</issue>), <fpage>121</fpage>&#x2013;<lpage>137</lpage>. <pub-id pub-id-type="doi">10.1038/nrneph.2017.165</pub-id> </citation>
</ref>
<ref id="B32">
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Vico</surname>
<given-names>T. A.</given-names>
</name>
<name>
<surname>Marchini</surname>
<given-names>T.</given-names>
</name>
<name>
<surname>Ginart</surname>
<given-names>S.</given-names>
</name>
<name>
<surname>Lorenzetti</surname>
<given-names>M. A.</given-names>
</name>
<name>
<surname>Ad&#xe1;n Are&#xe1;n</surname>
<given-names>J.&#x20;S.</given-names>
</name>
<name>
<surname>Calabr&#xf3;</surname>
<given-names>V.</given-names>
</name>
<etal/>
</person-group> (<year>2019</year>). <article-title>Mitochondrial Bioenergetics Links Inflammation and Cardiac Contractility in Endotoxemia</article-title>. <source>Basic Res. Cardiol.</source> <volume>114</volume> (<issue>5</issue>), <fpage>38</fpage>. <pub-id pub-id-type="doi">10.1007/s00395-019-0745-y</pub-id> </citation>
</ref>
<ref id="B33">
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Zanotti-Cavazzoni</surname>
<given-names>S. L.</given-names>
</name>
<name>
<surname>Hollenberg</surname>
<given-names>S. M.</given-names>
</name>
</person-group> (<year>2009</year>). <article-title>Cardiac Dysfunction in Severe Sepsis and Septic Shock</article-title>. <source>Curr. Opin. Crit. Care</source> <volume>15</volume> (<issue>5</issue>), <fpage>392</fpage>&#x2013;<lpage>397</lpage>. <pub-id pub-id-type="doi">10.1097/MCC.0b013e3283307a4e</pub-id> </citation>
</ref>
<ref id="B34">
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Zhang</surname>
<given-names>Q.</given-names>
</name>
<name>
<surname>Fu</surname>
<given-names>H.</given-names>
</name>
<name>
<surname>Zhang</surname>
<given-names>H.</given-names>
</name>
<name>
<surname>Xu</surname>
<given-names>F.</given-names>
</name>
<name>
<surname>Zou</surname>
<given-names>Z.</given-names>
</name>
<name>
<surname>Liu</surname>
<given-names>M.</given-names>
</name>
<etal/>
</person-group> (<year>2013</year>). <article-title>Hydrogen Sulfide Preconditioning Protects Rat Liver against Ischemia/reperfusion Injury by Activating Akt-GSK-3&#x3b2; Signaling and Inhibiting Mitochondrial Permeability Transition</article-title>. <source>PloS one</source> <volume>8</volume> (<issue>9</issue>), <fpage>e74422</fpage>. <pub-id pub-id-type="doi">10.1371/journal.pone.0074422</pub-id> </citation>
</ref>
<ref id="B35">
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Zhu</surname>
<given-names>Y.</given-names>
</name>
<name>
<surname>Liu</surname>
<given-names>L.</given-names>
</name>
<name>
<surname>Peng</surname>
<given-names>X.</given-names>
</name>
<name>
<surname>Ding</surname>
<given-names>X.</given-names>
</name>
<name>
<surname>Yang</surname>
<given-names>G.</given-names>
</name>
<name>
<surname>Li</surname>
<given-names>T.</given-names>
</name>
</person-group> (<year>2013</year>). <article-title>Role of Adenosine A2A Receptor in Organ-specific Vascular Reactivity Following Hemorrhagic Shock in Rats</article-title>. <source>J.&#x20;Surg. Res.</source> <volume>184</volume> (<issue>2</issue>), <fpage>951</fpage>&#x2013;<lpage>958</lpage>. <pub-id pub-id-type="doi">10.1016/j.jss.2013.03.039</pub-id> </citation>
</ref>
</ref-list>
</back>
</article>